A Multicenter, Observational Study of the Long-Term Safety of Infliximab (REMICADE) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD). RESULTS COPD: REMICADE Safety Under Long Term Study in COPD.

Trial Profile

A Multicenter, Observational Study of the Long-Term Safety of Infliximab (REMICADE) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD). RESULTS COPD: REMICADE Safety Under Long Term Study in COPD.

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Sep 2013

At a glance

  • Drugs Infliximab (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions
  • Acronyms RESULTS COPD
  • Sponsors Janssen Biotech
  • Most Recent Events

    • 14 Feb 2012 Trial phase changed from III to IV as reported by ClinicalTrials.gov.
    • 14 Feb 2012 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
    • 14 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top